Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.61 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.61 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.61 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | GALK1 | P51570 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28162884 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL6570199 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL27639803 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL6507790 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL7144990 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL7141014 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL6570202 | 1.00 | LGALS9 (0.61) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL8762538 | 0.98 | LGALS9 (0.60) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL10524702 | 0.98 | LGALS9 (0.60) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB | |
| SCHEMBL9451232 | 0.98 | LGALS9 (0.60) | LGALS9LGALS1LGALS3LGALS7; LGALS7BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027359-B9 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1027359-B1 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | LGALS9 342/4885LGALS1 240/4885LGALS3 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.